CN112263648A - Traditional Chinese medicine for preventing and treating cerebral arterial thrombosis - Google Patents
Traditional Chinese medicine for preventing and treating cerebral arterial thrombosis Download PDFInfo
- Publication number
- CN112263648A CN112263648A CN202011272975.1A CN202011272975A CN112263648A CN 112263648 A CN112263648 A CN 112263648A CN 202011272975 A CN202011272975 A CN 202011272975A CN 112263648 A CN112263648 A CN 112263648A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- group
- preventing
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The invention discloses a traditional Chinese medicine for preventing and treating cerebral arterial thrombosis, which comprises the following raw materials in percentage by mass: 1000 parts of pallas pit viper powder, 1000 parts of astragalus powder, 500 parts of suberect spatholobus stem powder, 100 parts of leech powder, 100 parts of earthworm powder, 100 parts of szechuan lovage rhizome powder, 100 parts of salvia powder, 100 parts of gastrodia tuber powder and 1 part of musk powder. The pallas pit viper and the astragalus root are monarch drugs and can tonify qi and activate blood; rhizoma Gastrodiae, Hirudo, and Saviae Miltiorrhizae radix as ministerial drugs for eliminating phlegm and removing blood stasis; the hemlock parsley, the suberect spatholobus stem, the earthworm and the musk are mutually used as assistants to promote blood circulation and enter brain orifices; the medicines are combined to play the effects of promoting blood circulation, removing blood stasis, tonifying deficiency and dredging collaterals, is safe to take, has no side effect, and can be used for preventing and treating ischemic stroke.
Description
Technical Field
The invention relates to a traditional Chinese medicine, in particular to a traditional Chinese medicine which is safe to take and has good effect in preventing and treating cerebral arterial thrombosis.
Background
Ischemic cerebral apoplexy is also called cerebral infarction, stroke or stroke in traditional Chinese medicine, and is characterized in that cerebral tissue ischemia and hypoxia lesion necrosis is caused by blood supply disorder in local cerebral tissue areas caused by various reasons, and further, the clinically corresponding nerve function deficiency expression is generated. According to different pathogenesis, the traditional Chinese medicine composition is divided into cerebral thrombosis, cerebral embolism, lacunar infarction and the like, and is a high-incidence and high-risk type cerebrovascular disease. At present, western medicines of intravenous thrombolysis and intravascular treatment are mainly clinically used, the disease attack is preferably within 4.5 hours and 6 hours, and the later period mainly depends on rehabilitation exercise. Although the existing traditional Chinese medicine preparations such as Xinnaokang capsules, Naoxintong capsules, salvia miltiorrhiza and the like are applied to clinically preventing and treating ischemic stroke, the clinical effect is not ideal and corresponding problems exist. The compound salvia miltiorrhiza dropping pill formula contains borneol, is easy to cause gastrointestinal injury to cause gastritis, gastric ulcer and other diseases, so the compound salvia miltiorrhiza dropping pill is not suitable for long-term administration, and particularly needs to be used with cautions for patients with deficiency-cold spleen and stomach. The Naoxintong capsule also has certain side effects, can cause symptoms of nausea, diarrhea, dizziness, headache, insomnia, hypodynamia, fever and the like of patients after being taken for a long time, has hidden dangers of damaging gastrointestinal tracts and nervous systems, and can cause adverse reactions related to scorpion toxicity in the medicine.
Disclosure of Invention
The invention aims to solve the technical problems in the prior art and provides a traditional Chinese medicine which is safe to take and has a good effect in preventing and treating ischemic stroke.
The technical solution of the invention is as follows: the traditional Chinese medicine for preventing and treating ischemic stroke comprises the following raw materials in percentage by mass: 1000 parts of pallas pit viper powder, 1000 parts of astragalus powder, 500 parts of suberect spatholobus stem powder, 100 parts of leech powder, 100 parts of earthworm powder, 100 parts of szechuan lovage rhizome powder, 100 parts of salvia powder, 100 parts of gastrodia tuber powder and 1 part of musk powder. Can be made into capsule, tablet, honeyed pill, etc.
The pallas pit viper and the astragalus root are monarch drugs, and can tonify qi and activate blood; rhizoma Gastrodiae, Hirudo, and Saviae Miltiorrhizae radix as ministerial drugs for eliminating phlegm and removing blood stasis; the hemlock parsley, the suberect spatholobus stem, the earthworm and the musk are mutually used as assistants to promote blood circulation and enter brain orifices; the medicines are combined to play the effects of promoting blood circulation, removing blood stasis, tonifying deficiency and dredging collaterals, is safe to take, has no side effect, and can be used for preventing and treating ischemic stroke.
Drawings
FIG. 1 is a schematic diagram of the state of mice in each experimental group 24h after the mice are modeled in the embodiment of the present invention.
Fig. 2 is a comparison of blood rheology in rats according to an embodiment of the invention (n =15,
s) schematic representation.
Detailed Description
The traditional Chinese medicine for treating ischemic stroke is prepared by taking 1000 parts of Agkistrodon halys, 1000 parts of radix astragali, 500 parts of caulis Spatholobi, 100 parts of Hirudo, 100 parts of Lumbricus, 100 parts of rhizoma Ligustici Chuanxiong, 100 parts of Saviae Miltiorrhizae radix, 100 parts of rhizoma Gastrodiae and 1 part of Moschus in a mass ratio as raw materials, crushing into powder, sieving with a 100-mesh sieve to obtain fine powder, and mixing the fine powder with honey to prepare honeyed pills.
The first experimental example:
1. laboratory animal
SPF grade male KM mice 60, weighing 25 ± 5g, were provided by the SPF animal experimental centre of university of daintily [ animal use license number: SYXK- (Liao) 2018-.
2. Drugs and devices
Antithrombotic pills (honeyed pills prepared by the embodiment of the invention); xinnaokang capsules (Jilinmi kang pharmaceutical industry Co., Ltd., approved No.: Chinese medicine standard Z22025480); l-carrageenan (Shanghai jin Song industries Co., Ltd.); chloral hydrate (shanghai xin yu biotechnology limited); physiological saline (Jiangxi Kodao sanitary products Co.); disposable sterile syringes (Dalian JMS medical devices, Inc.); vernier calipers (japan sanfeng instrument); gavage needle (Beijing Lei Kong scientific and technological development Co., Ltd.).
3. Experimental methods
3.1 grouping and administration
Male KM mice, which were adaptively bred for one week, were randomly divided into six groups of 10 mice each, namely, a blank group, a model group, and a Xinnaokang capsule group (6.0 g.kg)-1) Antithrombotic pill low dose group (1.0 g kg)-1) The dose group of the antithrombotic pills is (2.0 g kg)-1) And antithrombotic pill high dose group (4.0 g kg)-1). Weighing, and infusing the corresponding medicine and normal saline into the stomach with the volume of 1mL/100g for 7 days at 1 time per day.
3.2 model preparation
A mouse tail thrombus model was prepared according to literature description in combination with preliminary experiment results. After the 7 th intragastric administration, the mice of each group except the blank group were injected with L-carrageenan (40 mg kg) intraperitoneally-1) And immersing the tail part of the fish in cold water at the temperature of 0-4 ℃ for low-temperature stimulation, fishing out after 1min and wiping the tail part.
3.3 numerical measurement
After 24 hours of molding, behavior changes of the mice were observed and anesthetized with 10% chloral hydrate (1 mL/300 g), and then the total length of the tail of the mice and the thrombus length were measured with a vernier caliper while photographs of the thrombus of the tail of the mice were taken in units of groups.
3.4 data analysis
The experimental data are analyzed by SPSS 17.0 software, the one-way ANOVA (one-way ANOVA) analysis is adopted for the condition-meeting group, the nonparametric rank sum test analysis is adopted for the condition-not-meeting group, and the Fisher probability method is adopted for the black tail rate. The results of the analysis are expressed as mean. + -. standard deviation (
S) represents the number of the atoms in the molecule,P<0.05i.e. the difference is statistically significant.
4. Results of the experiment
4.1 changes in mouse behavioral State
The state of the blank group of mice is as normal, the model group of mice has poor diet, weak activity and intolerance of cold, the behavior state of the other groups of mice is obviously superior to that of the model group, and the mice are optimally selected by the dose of the antithrombotic pill.
4.2 mouse caudal Thrombus
After 24h of molding, as shown in fig. 1: dark red thrombi appear on the tails of all groups of mice in different degrees, and part of the thrombi on the tails of the mice dry and fall off to form broken tails. FIG. 1, A, model group; b, a Xinnaokang capsule group;
c, anti-thrombus pill low dose group; d, anti-thrombus pill medium dosage group; and E, an antithrombotic pill high-dose group.
As a result:
compared with a blank group of mice, the black tail rate of the model group of mice reaches 100 percent, the tail thrombus accounts for about 25 percent of the length of the whole tail, and the difference is obvious (P<0.01) Prompting the successful preparation of the model. Compared with the model group mice, the black tail rate, the tail thrombus length and the tail thrombus relative length of the Xinnaokang capsule group mice and the antithrombotic pill high-dose group mice are all reduced, but the differences are not obvious (P)>0.05); the tail thrombus length and the tail thrombus relative length of the anti-thrombus pill low and medium dose group mice and the black tail rate of the anti-thrombus pill medium dose group mice are reduced and have obvious difference (P<0.01OrP<0.05). See table 1 for details.
TABLE 1 comparison of Black-tailed Rate, Tail Thrombus Length and the relative Tail Thrombus Length in mice
| Grouping | Dosage (g.kg)-1·d-1） | Black tail rate of mice | Mouse tail thrombus length (mm) | Relative length of tail thrombus of mouse |
| Blank group | —— | —— | —— | —— |
| Model set | —— | 100%** | 19.45±7.51** | 23.52±9.42** |
| Capsule group for treating cardiovascular and cerebrovascular diseases | 6.0 | 75% | 11.38±14.01 | 13.30±16.22 |
| Antithrombotic pill low dose group | 1.0 | 60% | 6.26±6.52## | 7.12±7.46## |
| Anti-thrombus pill medium dosage group | 2.0 | 25%# | 4.31±8.06## | 4.91±9.19## |
| Antithrombotic pill high dose group | 4.0 | 75% | 16.49±12.78 | 18.76±14.80 |
Note: in comparison to the blank set, the data is,** P<0.01(ii) a In comparison to the set of models,# P<0.05；## P<0.01. Black tail rate = (number of mice with thrombus appearing at tail/total number of mice) × 100%; relative length of mouse tail thrombus = length of mouse tail thrombus/total length of mouse tail.
The results show that: the medicine provided by the embodiment of the invention can effectively prevent thrombus and is used as a medicine for preventing cerebral arterial thrombosis.
Experimental example 2:
1. experimental animals SPF-grade male SD rats (SPF animal experiment center of Dalian medical university, animal license number: SYXK- (Liao) 2018-.
2. Drugs and devices
Antithrombotic pills (honeyed pills prepared by the embodiment of the invention); naoxintong capsules (Shaanxi step-size pharmaceutical Co., Ltd., approved No.: national drug standard Z20025001, specification: 0.4 g.36 capsules/box); salvia miltiorrhiza (purchased from Dachaitang drugstore, Productivity: Henan) epinephrine hydrochloride injection (A)Adrenaline Hydrochloride Injection, Adr) (Shanghai Hefeng pharmaceuticals Co., Ltd., approved article No.: national standard character H31021062, specification: 1ml:1 mg).
SA-9000 automatic hemorheometer (schidcokfield technologies ltd, beijing seikco); RC-6plus is dropped to a high speed refrigerated centrifuge (Sammer fly technologies, Inc. USA); a disposable human vein collection container (zhengzhou mountain medical supplies ltd); BSA4202S electronic analytical balance (sartorius, germany).
3. Experimental methods
70 SPF male SD rats were randomly divided into 7 groups, namely blank group, model group, Naoxintong capsule group (6.0 g.kg)-1) Antithrombotic pill low dose group (1.0 g kg)-1) The dose group of the antithrombotic pills is (2.0 g kg)-1) High dose group of antithrombotic pills (4.0 g kg)-1) And Saviae Miltiorrhizae radix group (5.0 g.kg)-1). Weighing, and infusing the corresponding medicine and normal saline into the stomach with the volume of 1mL/100g for 7 days at 1 time per day. After the 7 th intragastric administration, other rats except the blank group were injected with Adr (0.8 mg/kg) repeatedly under the skin and were given a cold water bath for 5min to prepare an acute blood stasis model, and the behavioral changes thereof were observed. After the model is prepared, the continuous administration is carried out for 7d according to the administration method, the rat is anesthetized by 10% chloral hydrate (0.3 ml/100 g) after the last administration and the intragastric administration is carried out for 4h, the abdominal aorta is subjected to blood sampling in parallel, and the whole blood viscosity (200 s) is detected-1、30s-1、5s-1、1s-1) And plasma viscosity (100 s)-1) The indexes of Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), pregnancy related protein PAPP-A and the like in plasmｃA are detected by adopting an ELISA method.
The experimental data were statistically analyzed using graphpadprism8.0.2.263 software, with mean ± standard deviation(s) ((S))
±s) Formally, between groups
And (4) checking the test result,P<0.05i.e. the difference is statistically significant.
4. Results of the experiment
Rat post-modeling state: the blank group of rats had good diet as usual; the model group rats have inappetence, loose hair, dull eyes and slow movement; the state of the rats in the administration group is improved compared with that in the model group, and the state of the rats in the high-concentration anti-thrombus pill group is optimal.
And (3) testing results:
(1) whole blood viscosity (200 s) in model group rats compared to blank group-1、30s-1、5s-1、1s-1) And plasma viscosity (100 s)-1) (iii) elevated, significantly different (P<0.01 or P<0.05) Indicating the success of model preparation. Whole blood viscosity (200 s) of rats in the Naoxintong capsule group and the antithrombotic pill group was low, medium, and high in concentration as compared with the model group-1、30s-1、5s-1、1s-1) And plasma viscosity (100 s) of antithrombotic pill high concentration group rats-1) Decrease, difference is significant: (P<0.01 or P<0.05) See fig. 2 for details
(2) From three indexes measured by ELISA, the indexes of each concentration group of the antithrombotic pill and the brain-heart capsule group can be obviously improved, wherein the concentration group in the antithrombotic pill has the best effect and shows better effect than the brain-heart capsule group and the salvia miltiorrhiza group, and the three indexes are shown in Table 2.
TABLE 2 comparison of ELISA assays for VEGF, FGF and PAPP A in rat plasma groups: (
±s) Unit:
| group of | VEGF (ng/L) | FGF (ng/L) | PAPP A(mIU·mL-1) |
| Blank group | 94.53±10.54 | 100.38±3.41 | 1.65±0.26 |
| Model set | 136.26±8.14 | 145.49±28.37 | 6.38±0.83 |
| Naoxintong capsule group | 104.35±10.47# | 123.12±6.38# | 3.24±0.66# |
| Antithrombotic pill low concentration group | 102.42±13.58# | 119.62±12.67## | 2.05±0.37## |
| Concentration group in antithrombotic pill | 97.37±6.27## | 105.71±15.82## | 1.74±0.51## |
| Antithrombotic pill high concentration group | 111.51±8.73# | 127.58±14.71# | 4.62±1.02 |
| Salvia miltiorrhiza group | 120.75±9.42 | 136.26±13.42 | 4.78±0.73 |
In comparison to the set of models,# P<0.05,##P<0.01
the results show that: the medicine provided by the embodiment of the invention has the effects of reducing blood viscosity and resisting thrombus, and can be used as a medicine for preventing and treating ischemic stroke.
Claims (1)
1. The traditional Chinese medicine for preventing and treating ischemic stroke is characterized by comprising the following raw materials in parts by mass: 1000 parts of pallas pit viper powder, 1000 parts of astragalus powder, 500 parts of suberect spatholobus stem powder, 100 parts of leech powder, 100 parts of earthworm powder, 100 parts of szechuan lovage rhizome powder, 100 parts of salvia powder, 100 parts of gastrodia tuber powder and 1 part of musk powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011272975.1A CN112263648A (en) | 2020-11-14 | 2020-11-14 | Traditional Chinese medicine for preventing and treating cerebral arterial thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011272975.1A CN112263648A (en) | 2020-11-14 | 2020-11-14 | Traditional Chinese medicine for preventing and treating cerebral arterial thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112263648A true CN112263648A (en) | 2021-01-26 |
Family
ID=74339987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011272975.1A Pending CN112263648A (en) | 2020-11-14 | 2020-11-14 | Traditional Chinese medicine for preventing and treating cerebral arterial thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112263648A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053007A (en) * | 1989-12-30 | 1991-07-17 | 沈阳第一制药厂 | The preparation method of embolism dissolving capsule containing pallas pit viper venin |
| CN1060609A (en) * | 1991-06-20 | 1992-04-29 | 沈阳血栓病医疗中心 | With the drying compound method that is equipped with antithrombotic pill of natural Agkistrodon halys |
| CN101549133A (en) * | 2009-05-08 | 2009-10-07 | 王广锋 | Ablation and embolism extinguishing preparation of Chinese medicine |
| CN101912540A (en) * | 2010-08-20 | 2010-12-15 | 张跃平 | Medicament for treating cerebral infarction |
-
2020
- 2020-11-14 CN CN202011272975.1A patent/CN112263648A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053007A (en) * | 1989-12-30 | 1991-07-17 | 沈阳第一制药厂 | The preparation method of embolism dissolving capsule containing pallas pit viper venin |
| CN1060609A (en) * | 1991-06-20 | 1992-04-29 | 沈阳血栓病医疗中心 | With the drying compound method that is equipped with antithrombotic pill of natural Agkistrodon halys |
| CN101549133A (en) * | 2009-05-08 | 2009-10-07 | 王广锋 | Ablation and embolism extinguishing preparation of Chinese medicine |
| CN101912540A (en) * | 2010-08-20 | 2010-12-15 | 张跃平 | Medicament for treating cerebral infarction |
Non-Patent Citations (5)
| Title |
|---|
| 候安会: "治疗脑血栓100例疗效观察", 《中医药信息》 * |
| 张迪: "蝮龙抗栓丸治疗气虚血瘀型缺血性中风随机平行对照研究", 《实用中医内科杂志》 * |
| 李琳: "蝮龙溶栓片在头颈部疾病中的应用", 《中医杂志》 * |
| 王根荣: "中风秘方治疗脑梗死52例临床观察", 《中国中医药科技》 * |
| 王根荣: "自拟方治疗脑梗死52例临床观察", 《中国社区医师》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN101953909A (en) | Medicament for treating cerebral infarction and preparation method thereof | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN102552811A (en) | Oral Chinese medicine composition for treating apoplexy | |
| CN103948782B (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN102886033A (en) | Traditional Chinese medicine preparation for promoting postpartum recovery of parturients and shortening lochial time | |
| CN104161896A (en) | Medicine composition for treating anemia | |
| CN103520665A (en) | Chinese medicament for miscarriage prevention at early pregnant stage of pregnant woman and preparation method thereof | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN112263648A (en) | Traditional Chinese medicine for preventing and treating cerebral arterial thrombosis | |
| CN102973758A (en) | Traditional Chinese medicine composition for treating depression | |
| JPS5865221A (en) | Novel medicine based on extractant from algae | |
| CN101194982B (en) | Antidepressive Chinese medicine composition and method of preparing the same | |
| CN103550702A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis | |
| CN112156169A (en) | Traditional Chinese medicine composition for treating schizophrenia | |
| CN105535044A (en) | Medicine composition for preventing and treating encephalatrophy | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN110433226A (en) | A kind of Chinese medicine composition and preparation and its preparation method and application for treating urarthritis or hyperuricemia | |
| CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN1559573A (en) | Fuyankang soft capsule and its preparation method | |
| CN110051720B (en) | A Chinese medicinal decoction containing lignum Dalbergiae Odoriferae and its application as medicine for treating diabetes | |
| CN106361984A (en) | Nine-raw-material blood stanching powder and preparing method and application thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN106038926A (en) | Traditional Chinese medicine for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210126 |